The Consume Justice Foundation Alerts the Public of Third-Quarter Sales for Topamax Despite Reports of Topamax Side Effects

Share Article

The Consumer Justice Foundation, a for-profit corporation that is staffed by a team of professional consumer advocates whose mission is to alert the public of potential dangers associated with the use of prescription medications and whose URL can be found at, hereby alerts the public to the posting of third-quarter sales of Topamax by Johnson & Johnson, the manufacturer of this medication.

The Consumer Justice Foundation, a for-profit corporation comprised of a team of professional consumer advocates who provide free online resources to the public with regards to dealing with insurance companies and the potential dangers of prescription medications, hereby alerts consumers of the posting of the third-quarter sales of Topamax, an anticonvulsant medication that is manufactured by Johnson & Johnson.

Specifically, Johnson & Johnson reported that Topamax sales generated $117 million in revenue during the third quarter of 2011, which represents a drop of 7.9 percent when compared to the sales of Topamax during the second quarter of 2011. The company attributes this drop in sales to the invasion of generic equivalents to the market.

The release of these Topamax sales figures also comes on the heels of an FDA warning that was issued in June of 2011 regarding the dangers associated with Topamax side effects. In addition to this FDA warning, the agency also convened a panel of experts in September of 2011 to discuss the potential dangers of Topamax side effects in order to weigh those risks against the benefits of those who use the drug to treat such health conditions as migraine headaches and epilepsy.

These FDA actions were prompted by statistics revealed by the North American Antiepileptic Drug (AED) Pregnancy Registry, which was used by the FDA as a resource and that revealed that 1.4% of infants exposed to topiramate during pregnancy developed cleft lip or cleft palate, compared with 0.38-0.55% of infants exposed to other epilepsy drugs. Only 0.07% of children whose mothers did not take an anticonvulsant medication such as Topamax were born with these birth defects.

About the Consumer Justice Foundation

The Consumer Justice Foundation, whose Web site can be found at, is a for-profit organization that serves two purposes for consumers: (1) to provide educational information regarding the policies and procedures of large corporations and how they affect the average consumer; and (2) to provide news updates and resources that continue to update consumers regarding developments taken by corporations that include pharmaceutical drug companies, auto manufacturers and insurance companies so that consumers who have been harmed can use these informational resources to connect to an experienced professional who can help them. The team at the Consumer Justice Foundation is staffed by experienced and passionate consumer advocates whose mission is to raise the awareness of issues that could pose a risk of harm to those who may not otherwise be aware of the dangers they face.


Share article on social media or email:

View article via:

Pdf Print

Contact Author

Faith Anderson
Visit website